Tyra Biosciences Statistics
Share Statistics
Tyra Biosciences has 53.09M
shares outstanding. The number of shares has increased by -3.29%
in one year.
| Shares Outstanding | 53.09M |
| Shares Change (YoY) | -3.29% |
| Shares Change (QoQ) | -4.01% |
| Owned by Institutions (%) | 82.57% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 11,228 |
| FTD / Avg. Volume | 3.41% |
Short Selling Information
The latest short interest is 4.35M, so 8.2% of the outstanding
shares have been sold short.
| Short Interest | 4.35M |
| Short % of Shares Out | 8.2% |
| Short % of Float | 12.04% |
| Short Ratio (days to cover) | 18.42 |
Valuation Ratios
The PE ratio is -9.2 and the forward
PE ratio is -4.43.
Tyra Biosciences's PEG ratio is
1.35.
| PE Ratio | -9.2 |
| Forward PE | -4.43 |
| PS Ratio | 0 |
| Forward PS | 1.8 |
| PB Ratio | 2.32 |
| P/FCF Ratio | -11.29 |
| PEG Ratio | 1.35 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Tyra Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.81,
with a Debt / Equity ratio of 0.02.
| Current Ratio | 23.81 |
| Quick Ratio | 23.81 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.07 |
| Debt / FCF | -0.09 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,441,350 |
| Employee Count | 60 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -47.61% in the
last 52 weeks. The beta is 1.17, so Tyra Biosciences's
price volatility has been higher than the market average.
| Beta | 1.17 |
| 52-Week Price Change | -47.61% |
| 50-Day Moving Average | 9.76 |
| 200-Day Moving Average | 16.01 |
| Relative Strength Index (RSI) | 48.01 |
| Average Volume (20 Days) | 328,961 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -104.18M |
| Net Income | -86.48M |
| EBITDA | -85.96M |
| EBIT | -86.48M |
| Earnings Per Share (EPS) | -1.51 |
Full Income StatementBalance Sheet
The company has 91.97M in cash and 6.22M in
debt, giving a net cash position of 85.74M.
| Cash & Cash Equivalents | 91.97M |
| Total Debt | 6.22M |
| Net Cash | 85.74M |
| Retained Earnings | -251.31M |
| Total Assets | 363.56M |
| Working Capital | 332.87M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -69.77M
and capital expenditures -664K, giving a free cash flow of -70.44M.
| Operating Cash Flow | -69.77M |
| Capital Expenditures | -664K |
| Free Cash Flow | -70.44M |
| FCF Per Share | -1.23 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
